Why Some People Respond to Helminthic Therapy and Others Do Not

by

Why Some People Respond to Helminthic Therapy and Others Do Not

1. Type of Condition

Helminths work best in conditions where active immune overreaction drives symptoms (e.g., Crohn’s, ulcerative colitis, MS, asthma).

They are less effective when irreversible damage dominates (e.g., late-stage RA with joint destruction, type 1 diabetes after β-cell loss).

2. Individual Immune Baseline

Helminths expand regulatory T cells and promote anti-inflammatory cytokines (IL-10, TGF-β).

People with high baseline inflammation often feel stronger benefit.

Those whose immune systems are already partly regulated may see less change.

3. Genetics and Immune History

HLA haplotypes and cytokine gene variants affect how the body reacts to helminth antigens.

Early-life exposures (infections, antibiotics, gut microbiome shaping) leave long-term immune “imprints” that influence responsiveness.

4. Microbiome Compatibility

Helminths interact with gut bacteria and metabolites.

People with diverse, resilient microbiomes may integrate helminths more effectively.

Dysbiotic or depleted microbiomes may blunt the therapy’s impact.

5. Species and Dose

Different helminths act differently (Necator americanus, Trichuris suis, Hymenolepis diminuta).

Optimal dose varies tenfold between individuals. Too few = no effect; too many = side effects or intolerance.

6. Time and Consistency

Some notice rapid changes (likely microbiome or neuroimmune shifts).

Full immune recalibration usually takes months to years.

Stopping too early, or inconsistent dosing, reduces the chance of benefit.

7. Age and Disease Stage

Younger people generally respond better — their immune systems are more adaptable.

Older patients may still benefit, but response is slower and less predictable.

Early or mid-stage disease responds better than late-stage, damage-driven illness.

8. Patient Behavior

Desperation can lead to overdosing (“more is better”), which backfires by causing flares, GI upset, or anemia.

Careful, guideline-based dosing improves odds of success.

9. Environmental and Lifestyle Context

Nutrition (iron, vitamin D, fiber), stress, and co-existing conditions all shape outcomes.

Supportive environments help helminths establish a beneficial relationship with the host.

Core Principle: People Aren’t Machines

Even with a ~75% response rate, there will always be non-responders.

Every immune system is unique.

Autoimmune diseases differ in mechanism and stage.

Human biology is adaptive and variable.

A high success rate doesn’t mean universality — it means helminthic therapy fits many people’s biology, but not everyone’s.

References

Response Rate Statistics and Clinical Outcomes:

  • Summers, R. W., Elliott, D. E., Urban, J. F., Thompson, R. A., & Weinstock, J. V. (2005). Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology, 129(1), 286-294.
  • Croese, J., O’Neil, J., Masson, J., Cooke, S., Melrose, W., Pritchard, D., & Speare, R. (2006). A proof of concept study establishing Necator americanus in Crohn’s patients and reservoir donors. Gut, 55(1), 136-137.
  • Capron, M., et al. (2019). Efficacy of the hookworm-derived protein P28GST for treatment-resistant Crohn’s disease patients. Journal of Crohn’s & Colitis, 13(10), 1280-1290.

Immune System Mechanisms (Tregs and Cytokines):

  • White, M. P. J., McManus, C. M., & Maizels, R. M. (2020). Regulatory T-cells in helminth infection: induction, function and therapeutic potential. Immunology, 160(3), 248-260.
  • Johnston, C. J. C., et al. (2017). A structurally distinct TGF-β mimic from an intestinal helminth parasite potently induces regulatory T cells. Nature Communications, 8, 1741.
  • Maizels, R. M., & McSorley, H. J. (2016). Regulation of the host immune system by helminth parasites. Journal of Allergy and Clinical Immunology, 138(3), 666-675.

Microbiome Interactions:

  • Brosschot, T. P., & Reynolds, L. A. (2018). The impact of a helminth-modified microbiome on host immunity. Mucosal Immunology, 11(4), 1039-1046.
  • Shute, A., et al. (2021). Cooperation between host immunity and the gut bacteria is essential for helminth-evoked suppression of colitis. Microbiome, 9(1), 186.
  • Li, S., et al. (2023). Interaction between tissue-dwelling helminth and the gut microbiota drives mucosal immunoregulation. npj Biofilms and Microbiomes, 9, 43.
  • Reynolds, L. A., et al. (2015). Commensal-pathogen interactions in the intestinal tract: lactobacilli promote infection with, and are promoted by, helminth parasites. Gut Microbes, 5(4), 522-532.

Genetic and Individual Variability:

  • The influence of genetic and environmental factors and their interactions on immune response to helminth infections. (2022). Frontiers in Immunology, 13, 869900.
  • Ovsyannikova, I. G., et al. (2009). Influence of host genetic variation on rubella-specific T cell cytokine responses following rubella vaccination. Vaccine, 27(25-26), 3349-3358.
  • Dendrou, C. A., Petersen, J., Rossjohn, J., & Fugger, L. (2018). HLA variation and disease. Nature Reviews Immunology, 18(5), 325-339.
  • Bomhof, M. R., et al. (2024). The influence of HLA genetic variation on plasma protein expression. Nature Communications, 15, 6354.

Helminth Species and Dose Response:

  • Parker, W. (2022). Socio-medical studies of individuals self-treating with helminths provide insight into clinical trial design for assessing helminth therapy. Parasites & Vectors, 15(1), 413.
  • Feary, J., et al. (2009). Safety of hookworm infection in individuals with measurable airway responsiveness: a randomized placebo-controlled feasibility study. Clinical and Experimental Allergy, 39(7), 1060-1068.
  • Chapman, P. R., et al. (2021). Vaccination of human participants with attenuated Necator americanus hookworm larvae and human challenge in Australia: a dose-finding study and randomised, placebo-controlled, phase 1 trial. The Lancet Infectious Diseases, 21(12), 1725-1736.
  • Hoogerwerf, M. A., et al. (2019). New insights into the kinetics and variability of egg excretion in controlled human hookworm infections. Journal of Infectious Diseases, 220(6), 1044-1048.

Treatment Duration and Consistency:

  • Lamminpää, K., et al. (2024). Health-promoting worms? Prospects and pitfalls of helminth therapy. BioEssays, 46(9), 2400080.
  • Gazzinelli-Guimaraes, P. H., et al. (2021). Helminth-induced human gastrointestinal dysbiosis: a systematic review and meta-analysis reveals insights into altered taxon diversity and microbial gradient collapse. mBio, 12(3), e00975-21.

Environmental and Lifestyle Factors:

  • Williams, A. R., et al. (2017). A polyphenol-enriched diet and Ascaris suum infection modulate mucosal immune responses and gut microbiota composition in pigs. Veterinary Research, 48(1), 13.
  • Tee, E. S., et al. (2022). Gut microbiome of helminth-infected indigenous Malaysians is context dependent. eLife, 11, e71830.

Meta-analyses and Systematic Reviews:

  • Kumar, S., et al. (2021). Use of helminth therapy for management of ulcerative colitis and Crohn’s disease: a systematic review. Parasitology, 148(12), 1424-1439.
  • Haughton, J., et al. (2015). Human helminth therapy to treat inflammatory disorders- where do we stand? BMC Immunology, 16, 12.
  • Ayelign, B., et al. (2023). The effects of helminth infections on the human gut microbiome: a systematic review and meta-analysis. Frontiers in Microbiomes, 2, 1174034.